Cite
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: The ASPEN study
MLA
UMC Utrecht Holding, et al. A Randomized Phase 3 Trial of Zanubrutinib vs Ibrutinib in Symptomatic Waldenström Macroglobulinemia: The ASPEN Study. 2020. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1432112881&authtype=sso&custid=ns315887.
APA
UMC Utrecht Holding, MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Cancer, Tam, C. S., Opat, S., D’Sa, S., Jurczak, W., Lee, H.-P., Cull, G., Owen, R. G., Marlton, P., Wahlin, B. E., Garcia-Sanz, R., McCarthy, H., Mulligan, S., Tedeschi, A., Castillo, J., … Dimopoulos, M. A. (2020). A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: The ASPEN study.
Chicago
UMC Utrecht Holding, MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Cancer, Constantine S Tam, Stephen Opat, et al. 2020. “A Randomized Phase 3 Trial of Zanubrutinib vs Ibrutinib in Symptomatic Waldenström Macroglobulinemia: The ASPEN Study.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1432112881&authtype=sso&custid=ns315887.